Briacell Therap (BCTX) Competitors $7.87 +0.15 (+1.94%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.68 -0.20 (-2.48%) As of 09/5/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCTX vs. ABP, ATNF, AIMD, MTEX, MBRX, SYBX, EDSA, LSB, CYCC, and HOTHShould you be buying Briacell Therap stock or one of its competitors? The main competitors of Briacell Therap include Abpro (ABP), 180 Life Sciences (ATNF), Ainos (AIMD), Mannatech (MTEX), Moleculin Biotech (MBRX), Synlogic (SYBX), Edesa Biotech (EDSA), LakeShore Biopharma (LSB), Cyclacel Pharmaceuticals (CYCC), and Hoth Therapeutics (HOTH). These companies are all part of the "pharmaceutical products" industry. Briacell Therap vs. Its Competitors Abpro 180 Life Sciences Ainos Mannatech Moleculin Biotech Synlogic Edesa Biotech LakeShore Biopharma Cyclacel Pharmaceuticals Hoth Therapeutics Briacell Therap (NASDAQ:BCTX) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends. Do institutionals & insiders hold more shares of BCTX or ABP? 15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 5.7% of Briacell Therap shares are held by company insiders. Comparatively, 20.8% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, BCTX or ABP? Briacell Therap has higher earnings, but lower revenue than Abpro. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBriacell TherapN/AN/A-$4.79M-$83.18-0.09Abpro$180K95.76-$7.23MN/AN/A Do analysts prefer BCTX or ABP? Briacell Therap presently has a consensus price target of $320.00, suggesting a potential upside of 3,966.07%. Abpro has a consensus price target of $4.00, suggesting a potential upside of 1,760.47%. Given Briacell Therap's higher possible upside, analysts clearly believe Briacell Therap is more favorable than Abpro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, BCTX or ABP? Briacell Therap has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Abpro has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Does the media refer more to BCTX or ABP? In the previous week, Briacell Therap's average media sentiment score of 0.84 beat Abpro's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media. Company Overall Sentiment Briacell Therap Positive Abpro Neutral Is BCTX or ABP more profitable? Abpro's return on equity of 0.00% beat Briacell Therap's return on equity.Company Net Margins Return on Equity Return on Assets Briacell TherapN/A -479.97% -182.26% Abpro N/A N/A -241.16% SummaryBriacell Therap beats Abpro on 5 of the 9 factors compared between the two stocks. Get Briacell Therap News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCTX vs. The Competition Export to ExcelMetricBriacell TherapMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.33M$3.18B$5.83B$9.93BDividend YieldN/A2.26%6.70%4.52%P/E Ratio-0.0921.1076.1526.11Price / SalesN/A471.22564.25189.88Price / CashN/A45.7236.9959.28Price / Book-0.369.8711.486.09Net Income-$4.79M-$53.42M$3.29B$266.51M7 Day Performance1.29%2.93%1.27%0.46%1 Month Performance24.92%9.85%7.94%4.59%1 Year Performance-92.80%15.74%62.94%26.04% Briacell Therap Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCTXBriacell Therap2.6723 of 5 stars$7.87+1.9%$320.00+3,966.1%-92.8%$5.33MN/A-0.098ABPAbproN/A$0.24-1.1%$4.00+1,550.2%N/A$19.65M$180K0.0015Gap DownATNF180 Life Sciences0.3057 of 5 stars$3.08-6.8%N/A+18.5%$18.57MN/A-0.207Gap UpAIMDAinos0.4098 of 5 stars$4.11+7.0%N/A+27.2%$17.89M$20K-0.8240News CoverageAnalyst UpgradeShort Interest ↑Gap DownMTEXMannatech0.4185 of 5 stars$8.68+4.2%N/A+25.6%$17.77M$117.87M-4.25250Short Interest ↑Gap UpMBRXMoleculin Biotech3.1683 of 5 stars$0.55-5.1%$4.00+633.3%-84.4%$17.41MN/A0.0020Analyst RevisionGap DownSYBXSynlogicN/A$1.46-1.4%N/A+0.7%$17.31M$10K-18.2580EDSAEdesa Biotech1.2679 of 5 stars$2.44+0.6%$5.00+105.3%-42.9%$17.03MN/A-1.8420Gap UpLSBLakeShore Biopharma1.4754 of 5 stars$0.81-0.9%N/A-81.0%$17.03M$85.67M0.00773Positive NewsShort Interest ↓Gap DownCYCCCyclacel Pharmaceuticals1.2637 of 5 stars$7.49-0.8%N/A-97.2%$16.90M$40K-0.0114Positive NewsAnalyst DowngradeShort Interest ↓HOTHHoth Therapeutics2.5007 of 5 stars$1.23-1.6%$4.00+225.2%+25.5%$16.57MN/A-1.154 Related Companies and Tools Related Companies ABP Alternatives ATNF Alternatives AIMD Alternatives MTEX Alternatives MBRX Alternatives SYBX Alternatives EDSA Alternatives LSB Alternatives CYCC Alternatives HOTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCTX) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Briacell Therap Please log in to your account or sign up in order to add this asset to your watchlist. Share Briacell Therap With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
